Latest News Archive

Please select Category, Year, and then Month to display items

The first clinical PhD in nuclear medicine completed at the UFS

18 April 2024 | Story Andre Damons | Photo Charl Devenish

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans.

News Archive

Suspension of the South African Doping Control Laboratory (SADoCoL) by the World Anti-Doping Agency (WADA)

2016-05-04

The senior leadership of the UFS and the management of the South African Doping Control Laboratory (SADoCoL) take note of the decision by the World Anti-Doping Agency (WADA) to suspend the laboratory’s accreditation to perform doping control analysis on biological samples of athletes and sportsmen and -women until 30 September 2016. During this time of suspension, all sport-related samples will be sent for analysis to the WADA accredited laboratory in Qatar until the accreditation of SADoCoL is re-established. Analysis according to WADA accreditation will therefore not be interrupted during the period of the suspension of the accreditation of SADoCoL.

The announcement by WADA on 3 May 2016 follows a voluntary decision by SADoCoL in March 2016 to temporarily close the laboratory for some of its routine analytical duties for six months, as from 1 April 2016. The decision was taken in consultation with the senior leadership of the UFS and other role players, especially the Department of Sport and Recreation of South Africa (SRSA) and the South African Institute for Drug-Free Sport (SAIDS). SADoCoL is a specialised service laboratory of the University of the Free State (UFS) and has been in existence for more than thirty years.

Due to the ever-increasing demands on the number, variety and analytical sensitivity of compounds to be analysed according to the Prohibited List of WADA, technical and infrastructure adaptations need to be implemented in the laboratory continuously to keep up with the demands. Over the last year, SADoCoL has drastically increased its capacity in both personnel and infrastructure, to a point where these changes can be implemented for optimal performance of the laboratory. This has to be done while normal routine analysis continues, and it became clear that at present, implementation cannot be successfully accomplished together with the workload from normal routine analyses.

The time of suspension will be utilised to implement and test these new systems in order to achieve the standard presently required by WADA, as well as to perform development and improvements. This development will be performed in close collaboration with other role players in the anti-doping movement in South Africa, such as SAIDS and SRSA. Scientific development aid will also be acquired from other doping control laboratories worldwide in order to assure that the high analytical quality is maintained and expanded to meet the fast growing challenges in this field. The progress of the process will be closely monitored, and the upgraded methodologies will then, after rigorous testing, be implemented to ensure that the required analytical quality is maintained so as to obtain re-accreditation by WADA at the conclusion of the suspension period.

Issued by: Lacea Loader (Director: Communication and Brand Management)
Telephone: +27(0)51 401 2584 or +27 (0) 83 645 2454
E-mail: news@ufs.ac.za
Fax: +27 (0) 51 444 6393

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept